p.37 抽出テキスト

Imatinib

1st generation BCR-ABL TKI

2nd generation BCR-ABL TKI

3rd generation BCR-ABL TKI

Nilotinib

Dasatinib

Bosutinib

Ponatinib HTN HF HG AF DL Peric-E Pleu-E PH VascTox

BCR-ABL TKI-related cardiovascular toxicities

Very common: ≥10% incidence

Common: 1% to <10% incidence Uncommon: 0.1% to < 1% incidence

Rare: <0.1% incidence

QTc

Figure 14 Breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitor-related cardiovascular toxicities. AF, atrial fibrillation; BCR-ABL, breakpoint cluster region–Abelson oncogene locus; DL, dyslipidaemia; EMA, European Medicines Agency; FDA, Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; PAD, peripheral artery disease; Peric-E, pericardial effusion; PH, pulmonary hypertension; Pleu-E, pleural effusion; ↑QTc, corrected QT interval prolongation; TKI, tyrosine kinase inhibitors; VascTox, vascular toxicity (stroke, MI, PAD). Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.261 Figure developed from EMA prescribing information,252 FDA prescribing information.253 Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026